(E)-3;4;5-Trimethoxycinnamic acid
Product Sizes
100 mg
£ POA
HY-W050162-100MG
50 mg
£ POA
HY-W050162-50MG
1 g
£ POA
HY-W050162-1G
500 mg
£ POA
HY-W050162-500MG
10mM/1mL
£ POA
HY-W050162-10MM
About this Product
- SKU:
- HY-W050162
- Additional Names:
- TMCA
- CAS Number:
- 20329-98-0
- Extra Details:
- (E)-3;4;5-Trimethoxycinnamic acid (TMCA) is a cinnamic acid substituted by multi-methoxy groups. (E)-3;4;5-Trimethoxycinnamic acid is an orally active and potent GABAA/BZ receptor agonist. (E)-3;4;5-Trimethoxycinnamic exhibits favourable binding affinity to 5-HT2C and 5-HT1A receptor; with IC50 values of 2.5 and 7.6 μM; respectively. (E)-3;4;5-Trimethoxycinnamic acid shows anticonvulsant and sedative activity. (E)-3;4;5-Trimethoxycinnamic acid can be used for the research of insomnia; headache and epilepsy[1][2][3].
- Molecular Weight:
- 238.24
- Purity:
- 99.97
- References:
- [1]Zhao Z, et al. Research progress in the biological activities of 3,4,5-trimethoxycinnamic acid (TMCA) derivatives. Eur J Med Chem. 2019 Jul 1;173:213-227.|[2]Chen CY, et al. 3,4,5-Trimethoxycinnamic acid, one of the constituents of Polygalae Radix exerts anti-seizure effects by modulating GABAAergic systems in mice. J Pharmacol Sci. 2016 May;131(1):1-5. |[3]Lee CI, et al. 3,4,5-Trimethoxycinnamic acid (TMCA), one of the constituents of Polygalae Radix enhances pentobarbital-induced sleeping behaviors via GABAAergic systems in mice. Arch Pharm Res. 2013 Oct;36(10):1244-51.
- Research Area:
- Neurological Disease
- Shipping Conditions:
- Ambient
- Storage Conditions:
- -20[o]C; 3 years; 4[o]C; 2 years (Powder)
- Type:
- Proteins, Peptides, Small Molecules & Other Biomolecules: Small Molecules
- Pathway:
- GPCR/G Protein;Membrane Transporter/Ion Channel;Neuronal Signaling
